Albertina Cárdenas-Vargas

Albertina Cárdenas-Vargas

Auto-generated profile, based on publicly available information

Albertina Cárdenas-Vargas

Medical and Pharmaceutical Biotechnology Unit, Center for Research and Assistance in Technology and Design of the State of Jalisco A.C., 44270, Guadalajara, Jalisco, Mexico

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2025 in Current Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
ACAhtziri Socorro Carranza-Aranda
Ahtziri Socorro Carranza-Aranda
ASAnne Santerre
Anne Santerre
ASAldo Segura-Cabrera
Aldo Segura-Cabrera
ACAlbertina Cárdenas-Vargas
Albertina Cárdenas-Vargas
Moisés Martínez VelázquezMoisés Martínez Velázquez
Moisés Martínez Velázquez
SHSara Elisa Herrera-Rodríguez
Sara Elisa Herrera-Rodríguez
Background: Androgen receptor mutations, particularly T877A and W741L, promote prostate cancer (PCa). The main therapies against PCa use androgen receptor (AR) antagonists, including Bicalutamide; but these drugs lose their effectiveness over time. Chrysin is a flavonoid with several biological activities, including antitumoral properties; however, its potential as an antiandrogen must be explored. Objective: The present study aimed to characterize and compare the molecular interactions of chrysin with wild-type and mutated ARs and their cytotoxic effect in an in vitro model of PCa. Methods: The affinities and molecular interactions of Bicalutamide and chrysin for the wild-type and mutated forms of AR were assessed by molecular docking. The MTT assay was used to evaluate the cytotoxic effect of these ligands on the DU-145 (T877A) and PC3 (W741L) PCa cell lines and on non-tumoral RWPE-1 cells. Results: The molecular dockings predicted a higher affinity of chrysin for the mutated AR than the wild-type AR (WT-AR); meanwhile, Bicalutamide presented a higher affinity for WT-AR. The amino acid residues involved in molecular interactions within the binding site of these receptors changed according to the ligands and AR variants, affecting their affinity scores. Chrysin exerted a specific cytotoxic effect against the PCa tumoral cells but none against the non-tumoral cells. In contrast, Bicalutamide showed potent cytotoxicity against all cell lines. Thus, the cytotoxic effect of chrysin against the DU-145 and PC3 cell line may be related to its strong and specific molecular interaction with the mutated ARs. Conclusion: This study evidences the potential antiandrogen effect of chrysin on mutated AR and specific cytotoxicity against PCa cells, suggesting that this flavonoid should be further studied in vivo to confirm its potential for therapy of advanced PCa.